Materialise Nv ADR Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $276.1M-2.5% YoYTTM through 31 Dec 2024
Net Income $13.9M+87.0% YoYTTM through 31 Dec 2024
Free Cash Flow $7.1MTTM through 31 Dec 2024
Margins
| Current | |
|---|---|
| Gross Margin | 57.1% |
| EBITDA Margin | 4.6% |
| Operating Margin | 3.5% |
| Net Margin | 5.0% |
Returns
3.0%ROE
1.8%ROA
6.3%ROIC
Balance Sheet Health
Debt / Equity0.25x
Current Ratio1.86x
Net Debt-$70.8Mnet cash position
Cash & Equivalents$102.3M
Quality Metrics
Piotroski F-Score6 / 9
FCF Margin2.6%
Rule of 406.1
Earnings-Beat Rate75.0%
Multi-Year Trend
RevenueFY2024: $266.8M
Diluted EPSFY2024: $0.23
Dividend
No dividend
Capital Allocation
Capex Intensity8.9%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Materialise Medical | $134.2M | +15.4% | View detailsExpected to continue its strong upward revenue trajectory in 2026. |
| Materialise Software | $40.9M | -6.8% | View detailsCompleting the transition towards a cloud-based subscription business model in 2026. |
| Materialise Manufacturing | $92.5M | -13.2% | View detailsIntensifying its ongoing shift towards series manufacturing and dedicated focus sectors amid persistent macroeconomic headwinds. |
Financials converted at 0.9610 from EUR.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.